
Peter Anthony Campochiaro MD
Retinal Disease
Professor of Ophthalmology, Johns Hopkins University School of Medicine; George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience
Join to View Full Profile
1800 Orleans StreetMaumenee LobbyBaltimore, MD 21287
Phone+1 410-955-5080
Fax+1 410-955-0869
Dr. Campochiaro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Virginia Medical CenterResidency, Ophthalmology, 1979 - 1982
- Johns Hopkins UniversityInternship, Internal Medicine, 1978 - 1979
- Johns Hopkins University School of MedicineClass of 1978
- University of Notre DameB.S., Magna Cum Laude, 1970 - 1974
Certifications & Licensure
- MD State Medical License 1983 - 2026
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Achievement Award for Retinal Research Retinal Research Foundation and Retina Society, 2014
- America's Top Doctors Castle Connolly, 2007-2014
- Senior Research Achievement Award Macula Society, 2013
- Join now to see all
Clinical Trials
- Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions Start of enrollment: 2006 Jan 01
- The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot Start of enrollment: 2008 Jan 01
- SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy Start of enrollment: 2009 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.Arshad M Khanani, Peter A Campochiaro, Jordan M Graff, Dennis M Marcus, Daniel Miller
JAMA Ophthalmology. 2025-04-01 - Structural Updates to the Implant and Refill Needle of the Port Delivery Platform.Dante J Pieramici, Peter A Campochiaro, Margaret Chang, Ian Pearce, Carl D Regillo
Translational Vision Science & Technology. 2025-04-01 - Rabbit model of oxidative stress-induced retinal degeneration.Yogita Kanan, Jingwen Zhang, Alexandra Bernardo-Colón, Subrata Debnath, Mahmood Khan
Free Radical Biology & Medicine. 2025-04-01
Journal Articles
- The Mechanism of Cone Cell Death in Retinitis PigmentosaPeter Campochiaro, MD, ScienceDirect
- Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for retinal vein occlusion (ORVO) studyHafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian, Am J Ophthalmol, 1/16/2015
- Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyesChanna R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, Am J Ophthalmol, 1/1/2015
- Join now to see all
Books/Book Chapters
Lectures
- Mechanism of Cone Cell Death in Retinitis PigmentosaLecce, Italy, 2010; Cordoba, Argentina, 2010; Schepens Eye Research Institute, 2015 - 1/1/2015
- Pharmacologic Delivery with Gene Therapy1/1/2014
- Treatment of Macular Edema Due to Retinal Vein OcclusionsOsaka, Japan - 1/1/2014
- Join now to see all
Press Mentions
- ARVO Foundation Announces Recipient of 2025 Oberdorfer Award in Low Vision ResearchMarch 10th, 2025
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS MicroinjectorFebruary 21st, 2023
- 100, 100: Ending Diabetic Eye Disease, ForeverMay 16th, 2022
- Join now to see all
Grant Support
- Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseasesJOHNS HOPKINS UNIVERSITY2024–2028
- Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseasesJOHNS HOPKINS UNIVERSITY2024–2028
- Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseasesJOHNS HOPKINS UNIVERSITY2024–2028
- Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of ActionJOHNS HOPKINS UNIVERSITY2019–2028
- Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of ActionJOHNS HOPKINS UNIVERSITY2019–2028
- Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of ActionJOHNS HOPKINS UNIVERSITY2019–2028
- NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis PigmentosaJOHNS HOPKINS UNIVERSITY2022–2027
- Suprachoroidal nonviral gene transfer of engineered VEGF antagonistsJOHNS HOPKINS UNIVERSITY2020–2025
- New Treatments Of Ocular Neovascularization And Macular EdemaNational Eye Institute2012
- Oxidative Damage And Cone Cell Death In RPNational Eye Institute2007–2012
- The Role Of The Nicotinic Cholinergic Pathway In Retinopathy Of PrematurityNational Eye Institute2011
- Targeting Survival Factors For Ocular NeovascularizationNational Eye Institute2007–2011
- Molecular Signals Involved In Ocular NeovascularizationNational Eye Institute2002–2005
- Function Of Pdgfs And Fgfs In The Retina And RPENational Eye Institute2000–2004
- Retinal Neovascularization In Diabetic RetinopathyNational Eye Institute1999–2001
- Functions Of Pdgfs And Fgfs In The Retina And RPENational Eye Institute1994–1999
- Small Molecule Inhibitors Of Ocular NeovascularizationNational Eye Institute1998
- Pathogenic Mechanisms In Proliferative VitreoretinopathyNational Eye Institute1990–1993
- Pathogenic Mechanisms In Proliferative VitreoretinopathyNational Eye Institute1989–1990
- Mechanisms In Retinal Pigment Epithelial Cell MigrationNational Eye Institute1985–1988
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/peter-campochiaro
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: